Histrelin

Central Precocious Puberty

Histrelin is used to treat children with central precocious puberty (CPP). This condition causes the early onset of puberty, typically before age 8 in girls and age 9 in boys. The medication helps delay the development of secondary sexual characteristics, such as breast development or voice deepening, and helps manage rapid bone growth that can lead to shorter adult height.

Advanced Prostate Cancer

In adults, histrelin is used as a palliative treatment for advanced prostate cancer. It is intended to help manage and relieve the symptoms associated with the progression of the disease. It is important to note that while histrelin helps control symptoms, it is not a cure for prostate cancer.

Administration

This medication is typically administered as a small implant placed under the skin, usually in the inner upper arm. The implant provides a continuous, slow release of the medication into the body over an extended period of time.

Mechanism of Action

Histrelin belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) agonists. It works by acting on the pituitary gland to regulate the production of specific hormones in the body.

Hormone Suppression

Initially, histrelin may cause a temporary increase in hormone levels. However, with continuous delivery, the medication causes the pituitary gland to stop sending signals to the ovaries or testes. This results in a significant drop in the levels of sex hormones, including testosterone and estrogen.

Clinical Effects

In children experiencing central precocious puberty, lowering these hormone levels helps to:

• Slow down the early development of sexual characteristics.
• Delay the rapid bone maturation that can lead to shorter adult height.

The medication is usually administered as a subcutaneous implant, which allows for a slow and steady release of the drug into the system over a long period of time.

Common Side Effects

Histrelin may cause reactions at the site where the implant is inserted, as well as symptoms related to hormonal changes. Common side effects include:

• Redness, pain, swelling, itching, or bruising at the implant site.
• Hot flashes and increased sweating.
• Headache.
• Fatigue or feeling weak.
• Breast tenderness or enlargement.
• Mood swings, irritability, or emotional changes.
• Acne or skin rash.
• Weight gain.
• Temporary vaginal bleeding or discharge in children during the first few weeks of treatment.

Serious Side Effects

Seek medical attention immediately if you notice any of the following serious symptoms:

• Signs of an allergic reaction, including hives, skin rash, or swelling of the face, lips, or tongue.
• Seizures.
• Symptoms of increased pressure in the brain, such as severe headache, ringing in the ears, dizziness, nausea, or vision problems like blurred vision or seeing double.
• New or worsening psychiatric symptoms, such as depression, aggression, or thoughts of self-harm.
• Difficulty urinating, pain when urinating, or blood in the urine.
• New or worsening bone pain.
• Chest pain or sudden shortness of breath.

Pregnancy and Fertility

Histrelin should not be used by individuals who are pregnant or may become pregnant, as it can cause significant harm to a developing fetus. Effective non-hormonal birth control is typically recommended during treatment.

Initial Symptom Flare

During the first few weeks of treatment, histrelin may cause a temporary increase in certain hormones. This can lead to a brief worsening of symptoms, such as bone pain or urinary issues in those treated for prostate cancer, or the onset of puberty signs in children.

Psychiatric and Neurological Risks

• Emotional Changes: There have been reports of mood swings, irritability, aggression, and depression. In some cases, suicidal thoughts or behaviors have been identified as a potential risk with this class of medication.
• Seizures: Seizures have occurred in patients receiving histrelin, including those with no prior history of epilepsy. The risk may be higher for individuals with a history of seizures, head injuries, or those taking other medications that increase seizure risk.

Heart and Metabolic Health

Treatment may increase the risk of developing diabetes or worsening existing blood sugar control. There is also a potential risk for heart-related issues, including heart attack, stroke, or changes in the heart's electrical activity (QT prolongation).

Bone Density

Long-term use of histrelin may lead to a decrease in bone mineral density, which could increase the risk of developing osteoporosis or bone fractures.

Implant Site Complications

The surgical insertion and removal of the implant carry risks such as infection, bruising, or scarring. In some cases, the implant may break or move, making it difficult to remove.

Pregnancy Risks

Histrelin is not recommended for use during pregnancy. Evidence suggests that this medication may cause birth defects or lead to a miscarriage. Before starting treatment with a histrelin implant, healthcare providers typically perform a pregnancy test to confirm the patient is not pregnant.

If you become pregnant or suspect you might be pregnant while using histrelin, you should notify your healthcare provider immediately.

Contraception

Individuals of childbearing age should use effective contraception during treatment. Because histrelin affects hormonal balance, healthcare providers often recommend using non-hormonal birth control methods, such as:

• Condoms
• Diaphragms
• Spermicides

Breastfeeding

It is currently unknown if histrelin passes into human breast milk or if it could affect a nursing child. Due to the lack of safety data, it is important to discuss the risks and benefits with a healthcare professional before breastfeeding while using this medication.

Available Forms

Histrelin is administered as a subcutaneous implant. This small, flexible device is surgically placed under the skin, usually on the inner part of the upper arm, by a healthcare professional.

Strengths and Administration

The implant is designed to provide a steady, continuous release of medication over a long period. It is available in formulations intended for specific conditions:

• Advanced Prostate Cancer: A single implant provides continuous treatment for approximately 12 months.
• Central Precocious Puberty: A single implant provides continuous treatment for children with early-onset puberty for approximately 12 months.

The implant must be removed or replaced by a healthcare provider at the end of the treatment period.

FDA Approval and Indications

Histrelin is approved by the U.S. Food and Drug Administration (FDA) for two specific clinical uses:

• Advanced Prostate Cancer: It is indicated for the palliative treatment of advanced prostate cancer. In this context, it helps manage symptoms by suppressing the production of testosterone.
• Central Precocious Puberty (CPP): It is approved for use in children who begin puberty at an abnormally early age (typically before age 8 for girls and age 9 for boys).

Safety Communications

The FDA has monitored safety signals regarding the use of GnRH agonists, including histrelin. In 2017, the FDA identified a potential risk of serious psychiatric events in children treated for central precocious puberty. These events may include emotional lability, irritability, and aggression. Healthcare providers are encouraged to monitor patients for new or worsening psychiatric symptoms during treatment.

Regulatory Status of Administration

Histrelin is regulated as a prescription medication and is administered as a subcutaneous implant. This delivery method is designed to provide a continuous release of the medication over a 12-month period. Because the implant requires a minor surgical procedure for both insertion and removal, it must be managed by a healthcare professional in a clinical setting.

Cost Considerations

Histrelin is administered as a long-acting subcutaneous implant. Because it requires professional medical administration, the total cost of treatment involves more than just the price of the medication itself.

• Clinical Procedures: The implant must be surgically inserted and later removed by a healthcare provider. Patients may incur costs related to the office visit, the surgical procedure, and any local anesthesia used during the process.
• Insurance Benefits: Coverage for histrelin often falls under a medical benefit rather than a pharmacy benefit. The out-of-pocket cost will depend on the patient's specific insurance plan, including deductibles and coinsurance requirements.
• Treatment Indication: The specific formulation prescribed—whether for central precocious puberty or advanced prostate cancer—may affect how the medication is billed and covered.

Patients are encouraged to contact their insurance provider and the administering clinic to obtain a specific cost estimate before the procedure.